Alterity secures fda alignment for ATH434 phase 3 pathway
Alterity Therapeutics received official End-of-Phase 2 meeting minutes from the U.S. Food and Drug Administration confirming a registrational pathway for ATH434 in multiple system atrophy. The minutes confirm key elements of the Phase 3 program announced 9 June 2026, and indicate the FDA agreed that
<p>Alterity Therapeutics received official End-of-Phase 2 meeting minutes from the U.S. Food and Drug Administration confirming a registrational pathway for ATH434 in multiple system atrophy. The minutes confirm key elements of the Phase 3 program announced 9 June 2026, and indicate the FDA agreed that</p>